STVN stevanatogroup.com: Company Value to Revenue

Official company branding of Stevanato Group (STVN)

The margin growth of Stevanato Group S.p.A. was driven by premium syringes for GLP-1 drugs. The company's current price-to-sales ratio on the GURU.Markets chart confirms this trend, where 3277.48 reflects the latest metric value. The impeccable reputation of the Italian brand guarantees vaccine safety, while the rapid shortage of specialized packaging in the global market stimulates further business expansion.

stevanatogroup.com (STVN): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

STVN (Stevanato Group Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Initial company analysis:STVN (Stevanato Group)
Manufactured products of Stevanato

For Stevanato Group S.p.A. (STVN), changes in the EV/Sales valuation serve as an objective indicator of the business's market value relative to sales volume, excluding the impact of debt load on capitalization. This multiple reflects management's ability to maintain the company's premium status amid geopolitical instability and risks of disruptions in medical glass supply chains, signaling potential for a correction should revenue stagnate.

Direct competitors

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Teleflex Inc. TFX|Enterprise Value-to-Revenue Coefficient MMSI (Merit Medical Systems, Inc.)|NVST - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio ICU Medical Corp ICUI|XRAY: EV/Sales Multiple|LMAT (LeMaitre Vascular, Inc.) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue ATRC|STAA (STAAR Surgical) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ChromaDex (NAGE)|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple